Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial

Blood and Marrow Transplant Clinical Trials Network, Ephraim J. Fuchs, Paul V. O'Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


Results of 2 parallel phase 2 trials of transplantation of unrelated umbilical cord blood (UCB) or bone marrow (BM) from HLA-haploidentical relatives provided equipoise for direct comparison of these donor sources. Between June 2012 and June 2018, 368 patients aged 18 to 70 years with chemotherapy-sensitive lymphoma or acute leukemia in remission were randomly assigned to undergo UCB (n = 186) or haploidentical (n = 182) transplant. Reduced-intensity conditioning comprised total-body irradiation with cyclophosphamide and fludarabine for both donor types. Graft-versus-host disease prophylaxis for UCB transplantation was cyclosporine and mycophenolate mofetil (MMF) and for haploidentical transplantation, posttransplant cyclophosphamide, tacrolimus, and MMF. The primary end point was 2-year progression-free survival (PFS). Treatment groups had similar age, sex, self-reported ethnic origin, performance status, disease, and disease status at randomization. Two-year PFS was 35% (95% confidence interval [CI], 28% to 42%) compared with 41% (95% CI, 34% to 48%) after UCB and haploidentical transplants, respectively (P = .41). Prespecified analysis of secondary end points recorded higher 2-year nonrelapse mortality after UCB, 18% (95% CI, 13% to 24%), compared with haploidentical transplantation, 11% (95% CI, 6% to 16%), P = .04. This led to lower 2-year overall survival (OS) after UCB compared with haploidentical transplantation, 46% (95% CI, 38-53) and 57% (95% CI 49% to 64%), respectively (P = .04). The trial did not demonstrate a statistically significant difference in the primary end point, 2-year PFS, between the donor sources. Although both donor sources extend access to reduced-intensity transplantation, analyses of secondary end points, including OS, favor haploidentical BM donors. This trial was registered at as #NCT01597778.

Original languageEnglish (US)
Pages (from-to)420-428
Number of pages9
Issue number3
StatePublished - Jan 21 2021

Bibliographical note

Funding Information:
This work was supported by grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute of the National Institutes of Health.

Publisher Copyright:
© 2021 by The American Society of Hematology.


  • Acute Disease
  • Adult
  • Aged
  • Bone Marrow Transplantation/adverse effects
  • Cause of Death
  • Chronic Disease
  • Female
  • Fetal Blood/physiology
  • Graft vs Host Disease/epidemiology
  • HLA Antigens/immunology
  • Hematopoiesis
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Transplantation, Haploidentical/adverse effects
  • Treatment Outcome
  • Unrelated Donors
  • Young Adult

PubMed: MeSH publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase II
  • Journal Article
  • Research Support, N.I.H., Extramural


Dive into the research topics of 'Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial'. Together they form a unique fingerprint.

Cite this